Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data

Ítems similars

• Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability
  per: Kerbusch, Thomas, et al.
  Publicat: (2003)
• Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis
  per: Wählby, Ulrika, et al.
  Publicat: (2004)
• Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS
  per: Zingmark, Per-Henrik, et al.
  Publicat: (2004)
• Population pharmacokinetics and pharmacodynamics of oral etoposide
  per: Toffoli, Giuseppe, et al.
  Publicat: (2001)
• Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis
  per: Chládek, Jaroslav, et al.
  Publicat: (2002)